AARD
Aardvark Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$5.38
−6.11%Aug 20, 2026, 18:32 UTC
A lawsuit was filed against Aardvark Therapeutics, Inc. on behalf of certain investors who purchased shares between February 13, 2025 and May 14, 2026, with a deadline of October 31, 2026 for investors to act.
Aug 20, 2026, 13:54 UTC
Hagens Berman Sobol Shapiro LLP notified investors of a pending securities class action lawsuit against Aardvark Therapeutics, Inc. related to its IPO and subsequent securities purchases.
Source:Aug 14, 2026, 23:47 UTC
A class action lawsuit was filed against Aardvark Therapeutics, Inc. alleging the company misled investors about the viability and efficacy of its lead drug candidate ARD-101, covering purchasers of its IPO stock and securities during the Class Period from February 13, 2025 to May 14, 2026.
Source:Aug 11, 2026, 20:53 UTC
Aardvark Therapeutics reported its financial results for the second quarter of 2026 and provided business updates.
Source:Jun 2, 2026, 20:30 UTC
Aardvark Therapeutics stopped its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome, triggering a 56% share price drop and an investigation by Hagens Berman into possible securities law violations.